

**Gates & Cooper LLP**

Howard Hughes Center  
6701 Center Drive West, Suite 1050  
Los Angeles, California 90045

RECEIVED  
CENTRAL FAX CENTER

MAY 11 2004

**FAX TRANSMISSION TO USPTO**

TO: Commissioner for Patents  
Attn: Examiner To be assigned  
Patent Examining Corps  
Facsimile Center  
Alexandria, VA 22313-1450

FROM: William J. Wood  
OUR REF.: G&C 30435.152-US-I1  
TELEPHONE: (310) 642-4144

Total pages, including cover letter: 9

PTO FAX NUMBER: **703 872-9306**

If you do NOT receive all of the pages, please telephone us at (310) 641-8797, or fax us at (310) 641-8798.

Title of Document Transmitted:	INFORMATION DISCLOSURE STATEMENT AND FORM-1449 (COPIES OF REFERENCES ARE NOT REQUIRED)
Applicant:	Steven M. Dubinett et al.
Serial No.:	10/756,101
Filed:	January 13, 2004
Group Art Unit:	1616
Our Ref. No.:	G&C 30435.152-US-I1

Please charge all fees to Deposit Account No. 50-0494 of Gates & Cooper LLP.

By: 

Name: William J. Wood  
Reg. No.: 42,236

I hereby certify that this paper is being transmitted by facsimile to the U.S. Patent and Trademark Office on the date shown below.

  
Signature

5/12/04  
Date

WJW/amb

G&C 30435.152-US-I1

Due Date: May 13, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Steven M. Dubinett et al. Examiner: To be assigned  
Serial No.: 10/756,101 Group Art Unit: 1616  
Filed: January 13, 2004 Docket: G&C 30435.152-US-II  
Title: EX VIVO METHODS OF USING SECONDARY LYMPHOID ORGAN CHEMOKINE TO  
MODULATE PHYSIOLOGICAL PROCESSES IN MAMMALS

RECEIVED  
CENTRAL FAX CENTER

MAY 14 2004

## CERTIFICATE OF MAILING OR TRANSMISSION UNDER 37 CFR 1.8

I hereby certify that this correspondence is being filed via facsimile transmission to the U.S. Patent and Trademark Office on May 12, 2004.

By: 

Name: William J. Wood

Attn: Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

We are transmitting herewith the attached:

- ☒ Transmittal sheet, in duplicate, containing a Certificate of Mailing or Transmission under 37 CFR 1.8.  
☒ Information Disclosure Statement and Form PTO-1449 (copies of references are not required)

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers, if appropriate.

Please charge all fees to Deposit Account No. 50-0494 of Gates & Cooper LLP. A duplicate of this paper is enclosed.

Customer Number 22462GATES & COOPER LLP

Howard Hughes Center  
6701 Center Drive West, Suite 1050  
Los Angeles, CA 90045  
(310) 641-8797

By: 

Name: William J. Wood  
Reg. No.: 42,236  
WJW/amb

G&amp;C 30435.152-US-II

Due Date: May 13, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Steven M. Dubinett et al. Examiner: To be assigned  
Serial No.: 10/756,101 Group Art Unit: 1616  
Filed: January 13, 2004 Docket: G&C 30435.152-US-II  
Title: EX VIVO METHODS OF USING SECONDARY LYMPHOID ORGAN CHEMOKINE TO  
MODULATE PHYSIOLOGICAL PROCESSES IN MAMMALS

CERTIFICATE OF MAILING OR TRANSMISSION UNDER 37 CFR 1.8

I hereby certify that this correspondence is being filed via facsimile transmission to the U.S. Patent and Trademark Office on May 12, 2004.

By:   
Name: William J. Wood

Attn: Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:


We are transmitting herewith the attached:

- ☒ Transmittal sheet, in duplicate, containing a Certificate of Mailing or Transmission under 37 CFR 1.8.  
☒ Information Disclosure Statement and Form PTO-1449 (copies of references are not required)

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers, if appropriate.

Please charge all fees to Deposit Account No. 50-0494 of Gates & Cooper LLP. A duplicate of this paper is enclosed.

Customer Number 22462  
GATES & COOPER LLP  
Howard Hughes Center  
6701 Center Drive West, Suite 1050  
Los Angeles, CA 90045  
(310) 641-8797

By:   
Name: William J. Wood  
Reg. No.: 42,236  
WJW/amb

G&amp;C 30435.152-US-II

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Steven M. Dubinett et al.	Examiner:	To be assigned
Serial No.:	10/124,862	Group Art Unit:	1616
Filed:	April 18, 2002	Docket:	G&C 30435.121-US-U1
Title:	METHODS OF USING SECONDARY LYMPHOID ORGAN CHEMOKINE TO MODULATE PHYSIOLOGICAL PROCESSES IN MAMMALS		

CERTIFICATE OF MAILING OR TRANSMISSION UNDER 37 CFR 1.8

I hereby certify that this correspondence is being filed via facsimile transmission to the U.S. Patent and Trademark Office on May 12, 2004.

By: 

Name: William J. Wood

INFORMATION DISCLOSURE STATEMENT (37 C.F.R. §1.97(b))

Attn: Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted before the mailing date of a first Office Action on-the-merits. Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

In accordance with 37 C.F.R. §1.98(d)(2), a copy of each document or other information listed on the enclosed Form 1449 is not provided because it was previously cited by or submitted to the U.S. Patent and Trademark Office in parent application, U.S. Serial No. 10/124,862 filed on April 18, 2002.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to

establish that the reference(s) are not "prior art". Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Please direct any response or inquiry to the below-signed attorney at (310) 641-8797.

Respectfully submitted,

GATES & COOPER LLP  
Attorneys for Applicant(s)

Howard Hughes Center  
6701 Center Drive West, Suite 1050  
Los Angeles, California 90045  
(310) 641-8797

Date: May 12, 2004

By: 

Name: William J. Wood  
Reg. No.: 42,236  
WJW/amb

Date Faxed: May 12, 2004

Sheet 1 of 4

Form 1449* <b>INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION</b>	Doclet Number: G&C 30435.152-US-11	Application Number: 10/756,101
	Applicant: Steven M. Dubinett et al.	
	Filing Date: January 13, 2004	Group Art Unit: 1616

## U.S. PATENT DOCUMENTS - COPIES OF DOCUMENTS NOT REQUIRED

EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,767,097	06/16/98	Tam			
	5,871,723	02/16/99	Strieter et al.			
	6,403,370	06/11/02	Alemanly et al.			
	US2002/0034494 A1	03/21/02	Vicari et al.			
	US2003/0008840 A1	01/09/03	Vicari et al.			
	US2003/0138413 A1	07/24/03	Vicari et al.			

## FOREIGN PATENTS - COPIES OF DOCUMENTS NOT REQUIRED

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 00/38706	07/06/00	PCT				
	WO 96/06169	02/29/96	WIPO				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) COPIES OF DOCUMENTS NOT REQUIRED

	Arenberg et al., "Interferon-Gamma-Inducible Protein 10 (IP-10) is an Angiostatic Factor that Inhibits Human Non-Small Cell Lung Cancer (NSCLC) Tumorigenesis and Spontaneous Metastases," J. Exp. Med., 1996, 184: 981-992.
	Arenberg et al., "The Murine CC Chemokine, 6C-kine, Inhibits Tumor Growth and Angiogenesis in a Human Lung Cancer SCID Mouse Model," Cancer Immunol. Immunother., 2001, 49: 587-592

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

\*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

G&amp;C 30435.152-US-11

Date Faxed: May 12, 2004

Sheet 2 of 4

Form 1449* <b>INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION</b>	Docket Number: G&C 30435.152-US-11	Application Number: 10/756,101
	Applicant: Steven M. Dubinett et al.	
	Filing Date: January 13, 2004	Group Art Unit: 1616

	Baggiolini et al., "Human Chemokines: An Update," Ann. Rev. Immunol., 1997, 15: 675-705
	Bancherchau et al., "Dendritic Cells and the Control of Immunity," Nature, 1998, 392(6673): 245-252
	Bellone et al., "Tumor-Associated Transforming Growth Factor- $\beta$ and Interleukin-10 Contribute to a Systemic Th2 Immune Phenotype in Pancreatic Carcinoma Patients," Am. J. Pathol., 1999, 155(2): 537-547
	Brunda et al., "Antitumor and Antimetastatic Activity of Interleukin 12 Against Murine Tumors," J. Exp. Med., 1993, 178: 1223-1230
	Chan et al., "Secondary Lymphoid-Tissue Chemokine (SLC) Is Chemotactic for Mature Dendritic Cells," Blood, 1999, 93(11): 3610-3616
	Chu et al., "Examining the Immune Response in Sentinel Lymph Nodes of Mice and Men," Eur. J. Nuc. Med., 1999, 26(Supplement): s50-53
	Cyster, "Chemokines and the Homing of Dendritic Cells to the T Cell Areas of Lymphoid Organs," J. Exp. Med., 1999, 189(3): 447-450
	Dieu et al., "Selective Recruitment of Immature and Mature Dendritic Cells by Distinct Chemokines Expressed in Different Anatomic Sites," J. Exp. Med., 1998, 188(2): 373-386
	D. Dilloo et al., "Combined chemokine and cytokine gene transfer enhances antitumor immunity," Nature Medicine, Vol. 2, No. 10, October 1996, pages 1090-1095
	S. Dubinett et al., "Gene Therapy for Lung Cancer," Gene Therapy, 1998, 12(3): 569-594
	Fajardo et al., "Transforming Growth Factor $\beta$ 1 Induces Angiogenesis In Vivo With a Threshold Pattern," Lab. Invest., 1996, 74(3): 600-608
	Farber, "Mig and IP-10: CXC Chemokines That Target Lymphocytes," J. Leukoc. Biol., 1997, 61(3): 246-257
	Ferrara, "The Role of Vascular Endothelial Growth Factor in Pathological Angiogenesis" Breast Cancer Res. Treat., 1995, 36: 127-137
	Gabrilovich et al., "Production of Vascular Endothelial Growth Factor by Human Tumors Inhibits the Functional Maturation of Dendritic Cells," Nat. Med., 1996, 2(10): 1096-1103
	Halak et al., "Tumor-Induced Interleukin-10 Inhibits Type 1 Immune Responses Directed at a Tumor Antigen As Well As a Non-Tumor Antigen Present at the Tumor Site," Cancer Res., 1999, 59: 911-917
	Hedrick et al., "Identification and Characterization of a Novel $\beta$ Chemokine Containing Six Conserved Cysteines," J. Immunol., 1997, 159: 1589-1593

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

\*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

G&amp;C 30435.152-US-11

Date Faxed: May 12, 2004

Sheet 3 of 4

Form 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION	Docket Number: G&C 30435.152-US-II	Application Number: 10/756,101
	Applicant: Steven M. Dubinett et al.	
	Filing Date: January 13, 2004	Group Art Unit: 1616

		Hromas et al., "Isolation and Characterization of Exodus-2, a Novel C-C Chemokine with a Unique 37-Amino Acid Carboxyl-Terminal Extension," J. Immunol., 1997, 159: 2554-2558
		Hu et al., "Gene Modified Tumor Vaccine with Therapeutic Potential Shifts Tumor-Specific T Cell Response from a Type 2 to a Type 1 Cytokine Profile," J. Immunol., 1998, 161: 3033-3041
		Huang et al., "Non-small Cell Lung Cancer Cyclooxygenase-2-dependent Regulation of Cytokine Balance in Lymphocytes..." Cancer Res., 1998, 58(6): 1208-1216
		Jenb et al., "Cutting Edge: Species Specificity of the CC Chemokine 6CKine Signaling Through the CXCR Chemokine..." J. Immunol., 1999, 162: 3765-3769
		Johnson et al., "Interleukin-12, Dendritic Cells, and the Initiation of Host-Protective Mechanisms Against <i>Toxoplasma Gondii</i> ," J. Exp. Med., 1997, 186(11): 1799-1802
		Kellermann et al., "The CC Chemokine Receptor-7 Ligands 6CKine and Macrophage Inflammatory Protein-3 $\beta$ Are Potent Chemoattractants for In Vitro- and In Vivo-Derived Dendritic Cells," J. Immunol., 1999, 162: 3859-3864
		Loetscher et al., "Chemokine Receptor Specific for IP-10 and Mig: Structure, Function, and Expression in Activated T-Lymphocytes," J. Exp. Med., 1996, 184: 963-969
		Luster et al., "IP-10, a -C-X-C- Chemokine, Elicits a Potent Thymus-Dependent Antitumor Response In Vivo," J. Exp. Med., 1993, 178: 1057-1065
		Magdaleno et al., "Cyclin-Dependent Kinase Inhibitor Expression in Pulmonary Clara Cells Transformed with SV40 Large T Antigen in Transgenic Mice," Cell Growth & Diff., 1997, 8(2): 145-155
		Nagira et al., "Molecular Cloning of a Novel Human CC Chemokine Secondary Lymphoid-Tissue Chemokine That Is a Potent Chemoattractant for Lymphocytes and Mapped to Chromosome 9p13," J. Biol. Chem., 1997, 272(31): 19518-19524
		Nanda et al., "Induction of anti-self-immunity to cure cancer: meeting review; gene therapy, adoptive immunotherapy and antitumor recombinant vaccine production (conference report)", abstract, Cell, Vol. 82, No. 1, 1995, pages 13-17. Database Biotechds, Accession Number 1995-12009.
		Ogata et al., "Chemotactic Response Toward Chemokines and its Regulation by Transforming Growth Factor- $\beta$ 1 of Murine Bone Marrow Hematopoietic Progenitor Cell-Derived Different Subset of Dendritic Cells," Blood, 1999, 93(10): 3225-3232
		Sallusto et al., "Rapid and Coordinated Switch in Chemokine Receptor Expression During Dendritic Cell Maturation," Eur. J. Immunol., 1998, 28: 2760-2769
		S. Sharma et al., "Secondary Lymphoid Tissue Chemokine Mediates T Cell-Dependent Antitumor Responses In Vivo," J. of Immunology, 2000, 164: 4558-4563

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

\*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

G&amp;C 30435.152-US-II



Date Faxed: May 12, 2004

Sheet 4 of 4

Form 1449* <b>INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION</b>	Docket Number: G&C 30435.152-US-11	Application Number: 10/756,101
	Applicant: Steven M. Dubinett et al.	
	Filing Date: January 13, 2004	Group Art Unit: 1616

	Sharma et al., "T Cell-Derived IL-10 Promotes Lung Cancer Growth by Suppressing Both T Cell and APC Function," J. Immunol., 1999, 163: 5020-5028
	S. Sharma et al., "Secondary Lymphoid Organ Chemokine Reduces Pulmonary Tumor Burden in Spontaneous Murine Bronchoalveolar Cell Carcinoma," Cancer Research, 2001, 61: 6406-6412
	Soto et al., "The CC Chemokine 6CKine Binds the CXC Chemokine Receptor CXCR3," PNAS, USA, 1998, 95(14): 8205-8210
	Sozzani et al., "Cutting Edge: Differential Regulation of Chemokine Receptors During Dendritic Cell Maturation: A model for Their Trafficking Properties," J. Immunol., 1998, 161: 1083-1086
	Stolina et al., "Specific Inhibition of Cyclooxygenase 2 Restores Antitumor Reactivity by Altering the Balance of IL-10 and IL-12 Synthesis," J. Immunol., 2000, 164: 361-370
	Strieter et al., "Interferon $\gamma$ -Inducible Protein 10(IP-10), A Member of the C-X-C Chemokine Family, Is an Inhibitor of Angiogenesis," Biochem. Biophys. Res. Commun., 1995, 210(1): 51-57
	Sun et al., "Interleukin-10 Gene Transfer Activates Interferon- $\gamma$ and the Interferon- $\gamma$ -Inducible Genes Gbp-1/Mag-1 and Mig-1 in Mammary Tumors," Int. J. Cancer, 1999, 80: 624-629
	Tanabe et al., "Identification of a New Mouse $\beta$ -Chemokine, Thymus-Derived Chemotactic Agent 4, with Activity on T Lymphocytes and Mesangial Cells," J. Immunol., 1997, 159: 5671-5679
	Tannenbaum et al., "The CXC Chemokines IP-10 and Mig are Necessary for IL-12-Mediated Regression of the Mouse RENCA Tumor," J. Immunol., 1998, 161: 927-932
	Tsuji et al., "Cyclooxygenase Regulates Angiogenesis Induced by Colon Cancer Cells," Cell, 1998, 93: 705-716
	Voest et al., "Inhibition of Angiogenesis In Vivo by Interleukin 12," J. Natl. Cancer Inst., 1995, 87(8): 581-586
	Willmann et al., "The Chemokine SLC is Expressed in T Cell Areas of Lymph Nodes and Mucosal Lymphoid Tissues and Attracts Activated T Cells Via CCR7," Eur. J. Immunol., 1998, 28: 2025-2034
	Yoshida et al., "Secondary Lymphoid-Tissue Chemokine is a Functional Ligand for the CC Chemokine Receptor CCR7," J. Biol. Chem., 1998, 273(12): 7118-7122

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

\*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

G&amp;C 30435.152-US-11